Goldman Sachs’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.1M | Buy |
397,994
+96,484
| +32% | +$3.91M | ﹤0.01% | 1921 |
|
|
2025
Q1 | $15.5M | Sell |
301,510
-17,220
| -5% | -$885K | ﹤0.01% | 1896 |
|
|
2024
Q4 | $17.6M | Buy |
318,730
+49,955
| +19% | +$2.77M | ﹤0.01% | 1882 |
|
|
2024
Q3 | $8.84M | Buy |
268,775
+63,224
| +31% | +$2.08M | ﹤0.01% | 2355 |
|
|
2024
Q2 | $5.59M | Buy |
205,551
+1,821
| +0.9% | +$49.5K | ﹤0.01% | 2533 |
|
|
2024
Q1 | $7.41M | Sell |
203,730
-33,709
| -14% | -$1.23M | ﹤0.01% | 2289 |
|
|
2023
Q4 | $4.81M | Buy |
237,439
+137,377
| +137% | +$2.78M | ﹤0.01% | 2622 |
|
|
2023
Q3 | $1.78M | Buy |
100,062
+23,110
| +30% | +$411K | ﹤0.01% | 3163 |
|
|
2023
Q2 | $1.39M | Buy |
76,952
+48,387
| +169% | +$874K | ﹤0.01% | 3419 |
|
|
2023
Q1 | $359K | Sell |
28,565
-27,103
| -49% | -$341K | ﹤0.01% | 4249 |
|
|
2022
Q4 | $816K | Sell |
55,668
-53,060
| -49% | -$778K | ﹤0.01% | 3814 |
|
|
2022
Q3 | $1.86M | Buy |
108,728
+10,018
| +10% | +$172K | ﹤0.01% | 3419 |
|
|
2022
Q2 | $1.44M | Buy |
98,710
+70,454
| +249% | +$1.03M | ﹤0.01% | 3689 |
|
|
2022
Q1 | $475K | Buy |
28,256
+153
| +0.5% | +$2.57K | ﹤0.01% | 4598 |
|
|
2021
Q4 | $632K | Buy |
28,103
+1,623
| +6% | +$36.5K | ﹤0.01% | 4365 |
|
|
2021
Q3 | $571K | Sell |
26,480
-400
| -1% | -$8.63K | ﹤0.01% | 4312 |
|
|
2021
Q2 | $779K | Sell |
26,880
-2,114
| -7% | -$61.3K | ﹤0.01% | 4181 |
|
|
2021
Q1 | $934K | Buy |
+28,994
| New | +$934K | ﹤0.01% | 3961 |
|